Cryolife Inc (CRY) Holdings Cut by Penn Capital Management Co. Inc.

Penn Capital Management Co. Inc. reduced its stake in Cryolife Inc (NYSE:CRY) by 69.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 7,240 shares of the medical equipment provider’s stock after selling 16,204 shares during the quarter. Penn Capital Management Co. Inc.’s holdings in Cryolife were worth $205,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Advisors Asset Management Inc. purchased a new stake in shares of Cryolife during the fourth quarter worth about $32,000. Bessemer Group Inc. acquired a new stake in shares of Cryolife in the fourth quarter worth approximately $60,000. LS Investment Advisors LLC lifted its position in Cryolife by 126.0% during the fourth quarter. LS Investment Advisors LLC now owns 2,581 shares of the medical equipment provider’s stock valued at $73,000 after buying an additional 1,439 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in Cryolife by 113.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,793 shares of the medical equipment provider’s stock valued at $79,000 after buying an additional 1,484 shares in the last quarter. Finally, Highwater Wealth Management LLC acquired a new position in Cryolife during the fourth quarter valued at approximately $106,000. 71.34% of the stock is currently owned by institutional investors.

A number of research analysts have weighed in on CRY shares. Zacks Investment Research cut shares of Cryolife from a “buy” rating to a “hold” rating in a research report on Wednesday, January 16th. ValuEngine upgraded shares of Cryolife from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, January 2nd. Northland Securities reiterated a “buy” rating and set a $32.00 price objective on shares of Cryolife in a research note on Thursday, January 17th. Finally, Needham & Company LLC started coverage on shares of Cryolife in a research note on Wednesday, February 27th. They issued a “hold” rating and a $29.65 price target for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. Cryolife currently has an average rating of “Buy” and an average target price of $32.16.

In other news, Director Ronald D. Mccall sold 6,200 shares of the company’s stock in a transaction dated Thursday, February 21st. The stock was sold at an average price of $29.26, for a total value of $181,412.00. Following the transaction, the director now owns 137,699 shares in the company, valued at approximately $4,029,072.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Amy Horton sold 6,666 shares of the company’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $29.15, for a total value of $194,313.90. Following the completion of the transaction, the vice president now owns 103,713 shares in the company, valued at approximately $3,023,233.95. The disclosure for this sale can be found here. 4.40% of the stock is currently owned by insiders.

CRY stock traded down $0.22 during trading on Friday, hitting $27.55. The company had a trading volume of 225,366 shares, compared to its average volume of 230,493. The company has a market capitalization of $1.02 billion, a P/E ratio of 105.96 and a beta of 0.54. Cryolife Inc has a fifty-two week low of $21.35 and a fifty-two week high of $36.05. The company has a quick ratio of 3.87, a current ratio of 5.19 and a debt-to-equity ratio of 0.81.

Cryolife (NYSE:CRY) last issued its quarterly earnings results on Wednesday, February 13th. The medical equipment provider reported $0.05 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.12 by ($0.07). Cryolife had a negative net margin of 1.45% and a positive return on equity of 3.49%. The business had revenue of $67.80 million during the quarter, compared to analyst estimates of $67.10 million. Equities analysts anticipate that Cryolife Inc will post 0.31 EPS for the current year.

WARNING: This article was first posted by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/04/21/penn-capital-management-co-inc-sells-16204-shares-of-cryolife-inc-cry.html.

Cryolife Profile

CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.

Featured Article: What economic reports are most valuable to investors?

Institutional Ownership by Quarter for Cryolife (NYSE:CRY)

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.